Massive Bio works with a number of key partners around the world to deliver the best treatment options for people diagnosed with cancer. Through these collaborative relationships, patients, family members, and physicians worldwide have easy access to Massive Bio’s proprietary SYNERGY AI® clinical trial matching system and Virtual Tumor Board services. This provides assurance that no matter where patients live, they receive the latest available and most effective therapies for their unique situations.
Structured data on drugs, biomarkers, and clinical trials
Thomson Reuters' Clinical Genomics Toolkit is an important source of information, feeding our web-based curation platform with the latest molecular profiling tests, upcoming drugs, biomarkers and clinical trials.
Philips Healthworks is an accelerator program from Philips which aims to tackle some of the biggest and most complex challenges in healthcare. It offers aspiring entrepreneurs access to healthcare partners, global innovation hubs and technology platforms that, in turn, help startups, de-risk and accelerate time-to-revenue.
Optimal Research provides Just-in-Time clinical trial access solutions to sponsors, sites and patients involved in cancer research or looking for options. Its global site community can activate a clinical trial in 2-weeks from patient pre-qualification assuring every cancer patient can access any trial made available Just-in-Time by sponsors. Optimal Research helps providers and patients make local access to cutting edge therapies possible in real time.
Knowledge base development and precision oncology toolkits
Massive Bio works closely with Dr. Li Ding at the McDonnell Genome Institute in Saint Louis, developing databases and web interfaces to educate oncologists on how to interpret complex molecular profiles into patient-friendly content.
Vendor neutral evaluation of molecular profiling reports
In collaboration with Dr. Zeynep Gumus and her lab at the Icahn Institute of Genetics and Genomic Sciences, Massive Bio performs vendor-neutral evaluations of molecular profiling technologies. The goal is to make the reports easier to understand for both the local oncologist and patient, which leads to increased adoption of targeted treatments for the patient’s specific tumor. We achieve this by conducting ongoing surveys with oncologists and patients so we can continue to make, on molecular profile reports even more intuitive and insightful to treatment strategies.
Simulating cancer cells to shortlist effective treatments
Creators of ROSALIND, built a dynamic, programmable computer simulation of mutated cancer cell signaling pathways. ROSALIND helps determine which drugs are most likely to be effective at restoring normal cell function. This patented technology provides one of the algorithms Massive Bio uses to identify in on the personalized cancer treatment options, presented to our expert physicians and scientists on our Virtual Tumor Board.
War Memorial Hospital has served communities for more than 100 years and employs more than 880 individuals who are deeply committed to delivering patient-focused care.
Hematology Oncology Associates was established in Palm Beach County over 35 years ago, and has grown to include 7 Board Certified Hematologist and Oncologists in 3 convenient locations.
State-of-the-art technology platform
We l leverage SecondOpinionExpert’s cutting edge information technology and network of top medical experts with Massive Bio’s world-class multidisciplinary cancer team of medical oncologists, molecular diagnostic scientists, reimbursement experts, and data scientists. Our, partnership will make precision oncology accessible, affordable, and personalized for patients around the globe.
Remed Assistance operates in Europe, Middle East, and elsewhere worldwide to provide value-added medical tourism, health, and insurance services. Massive Bio expands its outreach by leveraging Remed Assistance’s vast international insurer network, granting their clients easy access to Massive Bio and our array of services.
Intergen conducts more than 1,500 varieties of genetic testing; Massive Bio is a channel partner of Intergen to provide tumor board services for already profiled patients.
Anadolu Medical Center provides healthcare services to patients from 30 countries in a most comprehensive and modern way. Massive Bio reviews complex cases for patients in Anadolu Center’s network who do not have the ability to come to the United States for care, but still want access to leading therapies they can receive at home.
Neolife is a leader in the oncology medical services market in Romania and one of the reference clinics for healthcare services in Central and Eastern Europe. Neolife and Massive Bio joined forces to support advanced staged cancer patients who require extensive treatment analysis US-based experts.
Genomize is a young, dynamic, and fast-growing biotech-startup specializing in genome-level data production and analysis. The company delivers years of bioinformatics know-how for project-specific needs in the pharmaceutical industry and multiple academic settings.
Onko Koçsel Pharmaceuticals has first taken its place in the pharmaceutical sector in 1987 by introducing blood derivative products in Turkey and becoming an exclusive distributor for the reputable European companies such as Caris Life Sciences Europe. Onto Koçsel is a channel partner of Massive Bio; uses its local sales force to train local oncologists in Massive Bio products and benefits of precision oncology.
Egypt Assistance was established in 2003 as a subsidiary of Remed Assistance. Egypt Assistance provides a wide range of services to its clients from various sectors, not only in Egypt but also in neighboring countries, especially UAE, Tunisia, and Morocco. They specialize in coordinating local and international travel, medical, legal assistance, and/or cost containment needs for their clients.
Interoperate with multiple health IT systems
Health IT systems traditionally have differences that make connecting with outside systems difficult. Our relationship with Redbox Engine allows us to easily exchange information between multiple systems, breaking down barriers that would otherwise cause delays in treatment planning. By linking to each hospital's raw HL7 formatted data, and translating it into a standardized nomenclature, Redox enables Massive Bio to create a platform that works with many different electronic medical record systems.